Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

by Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M
Published 2018-03-01

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

by Yingcheng Wang, Yingcheng Wang, Mingjun Rui, Mingjun Rui, Xin Guan, Xin Guan, Yingdan Cao, Yingdan Cao, Pingyu Chen, Pingyu Chen
Published 2021-06-01

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy

by Ghetti G, D'Avella MC, Pradelli L
Published 2021-02-01

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

by Eunae Jeong, Changjun Wang, Leslie Wilson, Lixian Zhong, Lixian Zhong
Published 2021-05-01

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

by Lee Cheng Phua, Soo Chin Lee, Kwong Ng, Mohamed Ismail Abdul Aziz
Published 2020-06-01

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer

by Dan Su, Bin Wu, Lizheng Shi
Published 2021-01-01

Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma

by I. S. Krysanov, V. S. Krysanova, B. Ya. Alekseev, V. Yu. Ermakova, E. V. Gameeva
Published 2020-07-01